You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
鍵凱科技(688356.SH):聚乙二醇伊立替康用於治療小細胞肺癌完成 II 期臨牀試驗數據分析
格隆匯 09-26 15:39

格隆匯9月26日丨鍵凱科技(688356.SH)公佈,聚乙二醇伊立替康(JK1201I)是公司自主研發的小分子長效抗癌1類創新藥物,該藥物是將伊立替康以聚乙二醇進行修飾後得到的新型化學藥品。在前期的非臨牀試驗中,JK1201I表現出了較市售鹽酸伊立替康更優的療效和安全性。在晚期實體瘤患者中完成的Ⅰ期臨牀試驗也表明JK1201I具有較好的安全性和耐受性,並且在小細胞肺癌患者中達到了部分緩解。

公司注射用聚乙二醇伊立替康(藥品代碼:JK1201I)用於小細胞肺癌治療的Ⅱ期臨牀試驗(稱“試驗”)完成Ⅱ期臨牀試驗數據分析並取得積極結果。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account